Mahzad Akbarpour to Ipilimumab
This is a "connection" page, showing publications Mahzad Akbarpour has written about Ipilimumab.
Connection Strength
0.055
-
Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy. Front Immunol. 2023; 14:1155778.
Score: 0.055
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.